Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Hypothalamic AmenorrheaHypogonadotropic Hypogonadism

Interventions

DRUG

Kisspeptin 112-121

SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Stephanie B. Seminara, MD

OTHER